Irregular Heartbeat Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com

July 30, 2018

DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “2018 Irregular Heartbeat Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Irregular Heartbeat Market” report has been added to ResearchAndMarkets.com’s offering.

Irregular Heartbeat refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Irregular Heartbeat condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Irregular Heartbeat pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Irregular Heartbeat pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Irregular Heartbeat pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

AETAS Pharma Co.,Ltd Armgo Pharma, Inc. Beijing CoSci Med-Tech Co.,Ltd Gilead Sciences, Inc. HUYA Bioscience International, LLC InCarda Therapeutics, Inc. LATITUDE Pharmaceuticals Inc. Milestone Pharmaceuticals Inc. Numerate, Inc. OMEICOS Therapeutics GmbH Ono Pharmaceutical Co., Ltd. Sanofi SA Servier Laboratories Limited Sign Path Pharma Inc

Key Topics Covered:

1 Table of Contents

2 Irregular Heartbeat Pipeline Analysis

3 Irregular Heartbeat- Company Wise Pipeline Analysis

4 Irregular Heartbeat R&D Pipeline Snapshots

5 Recent Developments in Irregular Heartbeat Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/n7d7rr/irregular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005327/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Clinical Trials



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 06:59 AM/DISC: 07/30/2018 06:59 AM


Update hourly